
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences Inc. is experiencing a positive outlook due to an upward revision of its fiscal year 2026 earnings per share (EPS) estimates, indicating improved financial expectations amidst an expanding share count. The anticipated FDA approval of the MyoVista device and the rollout of the MyoVista Insights cloud software platform present a significant market opportunity, likely positioning the company for enhanced growth in the coming years. Additionally, the new price target of $9.20 suggests substantial potential upside, supported by net present value analysis reflecting investor confidence in the company's innovative AI-ECG diagnostic solutions.
Bears say
HeartSciences Inc. is facing significant financial challenges, as indicated by a substantial downward revision of its FY2026 revenue estimate from $1.2 million to only $0.1 million, primarily due to delays with the FDA. Additionally, the company is exposed to multiple risks, including liquidity and balance sheet issues, the potential for product candidates to fail in clinical trials, and challenges related to regulatory approvals and commercialization of its technologies. The myriad of risks posed by competition, changes in macroeconomic factors, and evolving investor sentiment further contribute to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares